Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 204.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 745 shares of the biopharmaceutical company’s stock after buying an additional 500 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Regeneron Pharmaceuticals were worth $333,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Fortaleza Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 101.6% during the third quarter. Fortaleza Asset Management Inc. now owns 1,230 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 620 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $3,384,000. Calamos Advisors LLC grew its position in Regeneron Pharmaceuticals by 492.5% during the third quarter. Calamos Advisors LLC now owns 69,222 shares of the biopharmaceutical company’s stock worth $30,951,000 after buying an additional 57,538 shares in the last quarter. Calamos Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $668,000. Finally, State of New Jersey Common Pension Fund D acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $1,341,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP Robert E. Landry sold 526 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total transaction of $248,371.94. Following the sale, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,296,456.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. Insiders have sold 89,468 shares of company stock worth $42,312,448 over the last ninety days. Insiders own 10.80% of the company’s stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the firm earned $2.82 earnings per share. The business’s revenue for the quarter was up 21.2% on a year-over-year basis.
A number of research firms recently weighed in on REGN. Morgan Stanley reissued an “equal weight” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Barclays PLC downgraded Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $450.00 to $395.00 in a research report on Friday, October 20th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Leerink Swann reissued an “outperform” rating and set a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Four investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $488.57.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.